Annual Report

The report records 2016 operating income growth of 15.58% and increased R&D investment, which rose 26.37% year on year. The company also advanced its precision-pharmaceutical business through investments and the establishment of related diagnostic and gene-testing entities. Its social responsibility section discusses employee rights and environmental protection, including the absence of major environmental and production incidents at its enterprises during the year.